Can't wait to see the actual study. This could be a really big deal.
https://thecanadian.news/2021/01/23...ffectiveness-of-colchicine-to-treat-covid-19/
A large study launched last March by the Montreal Heart Institute allows a “major breakthrough” in the treatment of COVID-19. Its results show that the anti-inflammatory drug colchicine is effective in treating the disease and preventing its complications. It is the first oral medicine proven to be effective in treating patients before they are admitted to hospital.
“We have just provided the planet with hope, exclaims the D.r Jean-Claude Tardif, principal investigator of the COLCORONA study and director of the research center of the Montreal Heart Institute (ICM). We finally have a first treatment that can help patients with COVID before their hospitalization to prevent hospitalizations, prevent intubations and prevent death. ”
In 4,159 patients proven to be diagnosed with COVID-19 using a PCR test, colchicine resulted in a 25% decrease in hospitalizations, a 50% decrease in the use of ventilation and a decrease in deaths by 44%. “It’s a major breakthrough,” says Dr Late.
Colchicine works to prevent the “major inflammatory storm” that affects the lungs and can send patients to hospital.
Colchicine is an anti-inflammatory drug commonly used in cardiology. It was discovered in the 19th century and initially used against gout. Some of its advantages are its low cost and few side effects. The Dr Tardif has been studying it for several years for heart disease and has shown that it reduces the risk of recurrence in cardiac patients by more than a quarter.
The study was launched by the ICM, with the help of a team from across the province last March. Among the more than 4000 participants, 3000 were in Quebec. The others were in the United States, Brazil, Spain and South Africa. Participants had to be diagnosed with COVID-19, be over 40, and be at least at risk of complications, such as diabetes or asthma.
This is a randomized, double-blind, placebo-controlled study that provides the highest level of certainty in scientific research.
This means that one group of patients received colchicine and another group received a placebo. Neither the patients nor the researchers knew who received what at the time of the study, ensuring reliable results.
https://thecanadian.news/2021/01/23...ffectiveness-of-colchicine-to-treat-covid-19/
A large study launched last March by the Montreal Heart Institute allows a “major breakthrough” in the treatment of COVID-19. Its results show that the anti-inflammatory drug colchicine is effective in treating the disease and preventing its complications. It is the first oral medicine proven to be effective in treating patients before they are admitted to hospital.
“We have just provided the planet with hope, exclaims the D.r Jean-Claude Tardif, principal investigator of the COLCORONA study and director of the research center of the Montreal Heart Institute (ICM). We finally have a first treatment that can help patients with COVID before their hospitalization to prevent hospitalizations, prevent intubations and prevent death. ”
In 4,159 patients proven to be diagnosed with COVID-19 using a PCR test, colchicine resulted in a 25% decrease in hospitalizations, a 50% decrease in the use of ventilation and a decrease in deaths by 44%. “It’s a major breakthrough,” says Dr Late.
Colchicine works to prevent the “major inflammatory storm” that affects the lungs and can send patients to hospital.
Colchicine is an anti-inflammatory drug commonly used in cardiology. It was discovered in the 19th century and initially used against gout. Some of its advantages are its low cost and few side effects. The Dr Tardif has been studying it for several years for heart disease and has shown that it reduces the risk of recurrence in cardiac patients by more than a quarter.
The study was launched by the ICM, with the help of a team from across the province last March. Among the more than 4000 participants, 3000 were in Quebec. The others were in the United States, Brazil, Spain and South Africa. Participants had to be diagnosed with COVID-19, be over 40, and be at least at risk of complications, such as diabetes or asthma.
This is a randomized, double-blind, placebo-controlled study that provides the highest level of certainty in scientific research.
This means that one group of patients received colchicine and another group received a placebo. Neither the patients nor the researchers knew who received what at the time of the study, ensuring reliable results.
-
2
- Show all
